Property:Has Toxicity Explanation
From Glioblastoma Treatments
Jump to navigationJump to search
S
Silibinin is considered to have few side effects, with gastrointestinal disturbances being the most common. +
Sulforaphane is considered to have low toxicity and is generally well-tolerated as a dietary supplement. In high concentrations used in research settings, it may cause gastrointestinal discomfort, but these effects are minimal compared to conventional cancer therapies. +
T
Tamoxifen has been approved by FDA for breast cancer and while it is under investigation for glioblastoma, its high dosage use can lead to certain side effects. These include blood clots, potential risk of uterine cancer in women and impotence in men. Further, weight gain is also observed as a common side effect. Therefore, it is rated 3.5 in toxicity due to these common side effects and the potential serious health risks associated with its usage. +
Thalidomide, although it has shown promise in treating various cancers, has a high level of toxicity due to side effects such as deep vein thrombosis, peripheral neuropathy, constipation, somnolence, pyrexia, pain, and teratogenicity (risks to a developing fetus). As such, it's rated as 4 out of 5, with 5 being the most toxic. Keep in mind that these effects may vary from person to person, so it is important to discuss the risks and benefits with your healthcare provider. +
B
The combination of BCNU and Gliadel Wafers in treatment for glioblastoma is assigned a toxicity level of 4, this is relatively high on a scale of 1 to 5. This means that the treatment has serious side effects which may include low blood counts, pulmonary problems, infections, and seizures. Despite these side effects, the improvement in survival rates may make this treatment an important option for many patients. However, managing these side effects could potentially be challenging and may significantly impact the quality of life. It's important to discuss these risks and potential benefits with your healthcare provider. +
A
The drug ABT-414 is in phase 1 of its clinical trials. It demonstrates a tendency towards eye toxicities, especially causing blurred vision. This is an indication of potentially high toxicity. However, due to small sample size and other variables in the study, the evaluations should be taken with caution. It is advised to expect a higher level of toxicity until tested further in next clinical trial phases. +
P
The drug Procarbazine is considered quite toxic. This rating is based on the common side effects like hematological toxicity, which refers to potential harm to your blood cells, nausea, and neurological effects such as headache or dizziness. These side effects are relatively common and could significantly affect your day-to-day life. Remember, all treatments come with potential risks, and it's important to discuss these with your doctor. +
V
The drug Valganciclovir (Valcyte) has a relatively low toxicity level. This is measured on a scale between 1 and 5, with 1 being the least toxic and 5 the most toxic. While Valganciclovir is approved by the FDA, it is currently used for the treatment of CMV infections, and its use for glioblastoma is still investigational. Its common side effects include diarrhea, nausea, and neutropenia, which is a lower-than-normal count of neutrophils, a type of white blood cell that helps fight off infections. It also has a potential risk for causing birth defects. The toxicity rating takes into account these potential side effects and the current state of research on its use in treating glioblastoma. +
P
The drug being tested, a Proton Pump Inhibitor, is commonly used for heartburn and acid-related issues, and is now being tested for its potential benefits in treating cancer. Its side effects include common, non-severe symptoms like headache, nausea, diarrhea, abdominal pain, fatigue, and dizziness. Although these can be uncomfortable, they are manageable and often temporary. Thus, we rate its toxicity a 2 out of 5. However, the drug is still under preclinical and observational studies for its use in cancer treatment, meaning its effects are not fully understood. Always consult with your physician when considering new treatments. +
V
The most common adverse event reported is myelosuppression, including instances of neutropenia and lymphopenia. A few patients experienced serious adverse events possibly related to VAL-083, indicating a moderate toxicity profile. Ongoing monitoring and management of these side effects are essential to minimize risks to patients. +
M
The toxicity level for Methadone, when used for investigational purposes in treating glioblastoma, is relatively low. It is well-established for its use in pain management and replacement therapy for addiction, known to have common side effects such as nausea and constipation, which usually resolve after one month. It has been found to have potential as a chemosensitizer in glioma cells, meaning that it makes the cancer cells more sensitive to chemotherapy. However, this use is currently in the research and investigative stage. It's important to note that the side effects may vary among individuals, and adequate supervision from healthcare providers is necessary during administration of this treatment. +
C
The toxicity level of 2.5 indicates that Celecoxib (Celebrex) and other NSAIDs have a moderate level of side effects, which are mostly related to potential stomach issues with long-term use. However, Celebrex has been designed to minimize these issues. Even though their use in cancer treatment is experimental, these drugs are generally well-tolerated. A toxicity level of 5 would represent a treatment with severe and frequent side effects. +
The toxicity level of CBD (Cannabidiol) is relatively low. It's been reported to be generally well-tolerated, especially at doses used for epilepsy. Typically, side effects may include tiredness, diarrhea, and changes in appetite or weight. However, as it is currently under investigational use in cancer treatment, including glioblastoma, the potential toxicities specific to cancer patients, particularly those with glioblastoma, are not fully understood and are currently under active research. It's essential to discuss with your healthcare provider before starting any new treatment regimen. +
The toxicity level of CCNU is quite high due to several common side effects. Most notably, it can cause hematological toxicity, which means it can damage your blood cells and affect your body's ability to fight infections and clot properly. It can also cause nausea, vomiting, and pulmonary toxicity, which can lead to lung damage. On a scale from 1 to 5, with 5 being the most toxic, CCNU is rated as a 4. However, despite these side effects, the treatment showed promising results in a clinical trial. +
T
The toxicity level of Thyroid Hormone T4 Suppression Therapy is rated as a 2, which indicates a low level of toxicity. This is because the therapy is designed to suppress the hormone levels in the body and replace them with a synthetic version to help fight cancer cells. The side effects, such as fatigue, are typically manageable, especially when the treatment is carefully monitored. Nonetheless, this therapy is not without potential side effects and it is applied off-label, hence it's necessary to discuss with your healthcare provider. +
The toxicity level of this treatment is relatively high because it involves a combination of drugs repurposed for different conditions with Temodar, a chemotherapy drug used to treat brain tumors. While the exact toxicity can vary based on the specific combination, the potential for increased toxicity from the chemotherapy component remains a significant risk. This toxicity can result in side effects ranging from mild symptoms such as nausea and fatigue, to more severe ones like infections or bleeding. However, in some cases, the potential benefits, like potentially longer survival periods, may outweigh these risks. It should be noted that the safety and efficacy of these combinations are still under investigation, and results to date have been mixed. +
M
The toxicity of Sodium R Lipoate and Hydroxycitrate (METABLOC) has been assessed as relatively low. It's still undergoing early clinical evaluation, which means it hasn't caused any severe adverse reactions to this point. However, we lack specific information on its common side effects. It's important to remember that everybody's body responds differently to medications, so while the toxicity appears low, some individuals may still experience side effects. +
S
The treatment has a toxicity level of 2 out of 5 which means it is fairly low in toxicity. The most commonly reported side effects include fatigue, dizziness, nausea, and mouth irritation. Please remember, these side effects do not occur in everyone and can be managed with the help of your healthcare team. More research is needed to fully understand the long-term effects of this treatment. As it is not FDA-approved in the United States, one has to monitor carefully when and if the treatment becomes available depending on the approval in their country. +
C
The treatment mentioned, Cannabis and Cannabis-derived products like Sativex, generally have minimal side effects. These may include dry mouth, red eyes, and increased appetite, causing mild discomfort rather than serious complications. Therefore, the toxicity is considered low (rated 1 out of 5), meaning it's generally safe with a low risk of harm. However, please note that all individuals may respond differently, and it's important to discuss any new treatments with your healthcare provider. +
P
The treatment with Platinum Compounds (Cisplatin) is considered relatively high in toxicity due to potential side effects like kidney damage (Nephrotoxicity), hearing loss (ototoxicity), and nervous system damage (neurotoxicity). It's important for patients to discuss these risks with their healthcare provider before starting therapy. A toxicity level of 4 out of 5 means this treatment carries significant risks, but it may be necessary for managing glioblastoma. +
